Bipartisan FDA User Fee Reauthorization Is Good Starting Point
Wednesday, April 25, 2012
WASHINGTON, D.C. – Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Tom Harkin (D-Iowa) and Ranking Member Senator Mike Enzi (R-Wyo.) today said the Committee’s markup of FDA user fee reauthorization reflected a strong bipartisan effort.
“Today’s markup of the user fee agreement reauthorizations was an important step,” said Harkin and Enzi. “At a time when Congress has been deeply divided, today’s markup displayed strong bipartisan cooperation.”
Harkin and Enzi noted that this legislation builds upon the current user fee programs, which will expire in September. If new drug and medical device user fee agreements are not authorized before current ones expire, FDA must lay off nearly 2,000 employees. This would derail the premarket review programs, threatening patient access to new therapies, biomedical industry jobs, and America’s global leadership in biomedical innovation.
“In addition to user fees, this bill will reauthorize programs that have helped make medicines safer for millions of children, upgrade FDA’s tools to police the global drug supply chain and ensure that American patients get better access to safe, innovative medical devices and medicines,” said Harkin and Enzi. “This measure will also help reduce the risk of drug shortages.”
# # #
Recent News
- Alexander Opposes Nominees to NLRB Who Remained on Board After Court Found Their Appointments Unconstitutional [Ranking Member]
- Senate Health Committee Passes Alexander and Colleagues’ Bill to Fix Responsibility for Safety of Sterile Compounded Drugs [Ranking Member]
- Harkin Statement on HELP Committee Approval of a Full Slate of Five Nominees to the NLRB [Chairman]
- Harkin Statement on HELP Committee Passage of the Pharmaceutical Compounding Quality and Accountability Act and the Drug Supply Chain Security Act [Chairman]
- Harkin, Alexander, Roberts, Franken Release Report Outlining Urgent Need for Clear Regulatory Guidelines of Drug Compounders as Committee Approves Legislation [Ranking Member]
- Harkin, Alexander, Roberts, Franken Release Report Outlining Urgent Need for Clear Regulatory Guidelines of Drug Compounders as Committee Approves Legislation [Chairman]
